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Abstract
Background: The relapsing-remitting dynamics is a hallmark of autoimmune diseases such as Multiple Sclerosis
(MS). Although current understanding of both cellular and molecular mechanisms involved in the pathogenesis of
autoimmune diseases is significant, how their activity generates this prototypical dynamics is not understood yet.
In order to gain insight about the mechanisms that drive these relapsing-remitting dynamics, we developed a
computational model using such biological knowledge. We hypothesized that the relapsing dynamics in
autoimmunity can arise through the failure in the mechanisms controlling cross-regulation between regulatory and
effector T cells with the interplay of stochastic events (e.g. failure in central tolerance, activation by pathogens) that
are able to trigger the immune system.
Results: The model represents five concepts: central tolerance (T-cell generation by the thymus), T-cell activation, T-cell
memory, cross-regulation (negative feedback) between regulatory and effector T-cells and tissue damage. We enriched
the model with reversible and irreversible tissue damage, which aims to provide a comprehensible link between
autoimmune activity and clinical relapses and active lesions in the magnetic resonances studies in patients with
Multiple Sclerosis. Our analysis shows that the weakness in this negative feedback between effector and regulatory T-
cells, allows the immune system to generate the characteristic relapsing-remitting dynamics of autoimmune diseases,
without the need of additional environmental triggers. The simulations show that the timing at which relapses appear
is highly unpredictable. We also introduced targeted perturbations into the model that mimicked immunotherapies
that modulate effector and regulatory populations. The effects of such therapies happened to be highly dependent on
the timing and/or dose, and on the underlying dynamic of the immune system.
Conclusion: The relapsing dynamic in MS derives from the emergent properties of the immune system operating in a
pathological state, a fact that has implications for predicting disease course and developing new therapies for MS.
Background
Multiple Sclerosis (MS) is the prototypic autoimmune
disease with relapsing-remitting behaviour [1,2]. Clinical
relapses are the defining feature of MS and act as the
basis for categorizing different forms of the disease, as a
marker to define the disease’s natural history and to
measure the success of new therapies (Figure 1A).
A relapse in MS is a reflection of acute focal inflamma-
tory event in the central nervous system (CNS) that dis-
rupts neural conduction by damaging myelinated axons.
It is now known from natural history studies performed
using frequent MRI scanning that clinical relapses repre-
sent only a small proportion (less than 20%) of CNS
inflammatory events, indicated by the presence of con-
trast enhancing lesions [2-4]. The clinical relapse rate
during the relapsing-remitting phase of MS is around
one per year and decreases as the disease advances [5,6].
In MS, clinical relapses generally last for a month with
spontaneous partial or full recovery afterwards. Their
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distributions along time have not been associated with
any specific pattern or precipitator [2,7] although it has
been estimated that the presences of such relapses are
preceded in one third of cases by either infections or
stressful events [8,9]. In any case, a clear understanding
of environmental factors driving the presence of relapses
as well as the cellular and molecular mechanisms gov-
erning the relapse onset and resolution is still lacking.
Although pathogenesis of MS is still unknown, it is
proposed as a T-cell-mediated autoimmune disease,
since its characteristic activity pattern, including
relapses, is related to the temporally and spatially segre-
gated effects of activated T cells [10,11]. Healthy animals
and humans contain auto-reactive effector T cells in the
peripheral repertoire [12]. Although the activity and
function of auto-reactive T cells in humans is not well
understood, studies in non-human primates have shown
that these cells can be activated, and may occasionally
trigger a T-cell-mediated attack against the CNS [13].
However, the activation and clonal expansion of these
effector T cells (Teff) is believed to be inhibited by per-
ipheral tolerance mechanisms, among other factors by
the presence of active regulatory T cells (Treg) [14-18].
As a matter of fact, deficiency in Treg results in a fatal
autoimmune syndrome affecting multiple organs in
mice [19,20] and humans [21,22]. Moreover, several
reports suggest MS and type 1 diabetic patients may
have an impaired Treg function and an imbalance in
Teff-Treg homeostasis [23-25]. On the other hand ther-
apeutic CTLA-4 blocking with monoclonal antibodies
Figure 1 The relapsing-remitting dynamics of Multiple Sclerosis. A) Disease subtype classification based in the presence of relapses:
relapsing-remitting (RR), secondary-progressive (SP), primary-progressive (PP) and progressive-relapsing (PR); B) Representative patient with MS
whom underwent monthly MRI for 48 months. Number of contrast enhancing lesions (CEL; left Y axis), disability (measured with the EDSS scale;
right Y axis) and presence of clinical relapses counterpart (no scale)
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(ipilimumab) in cancer patients induces autoimmunity
[26]. In the periphery, for a given age and genetic back-
ground, the Treg population represents a stable propor-
tion of the CD4+ T cells in the steady state (10%),
suggesting that the homeostasis of Teff and Treg are
tightly co-regulated [27]. Thus, homeostasis of Treg is
likely to be an important process in the proper function-
ing of the immune system as well for controlling self-
reacting Teff cells and preventing autoimmunity
[20,28,29].
In order to gain insights in the cellular events leading
to the relapsing dynamics, we develop a computational
model of the adaptive immune system. We hypothesize
that the cross-regulation between Teff and Treg cells
that works as a negative feedback, coupled with stochas-
tic processes such as common infections (noise), is able
to buffer oscillations in the functioning of the immune
system, allowing at the same time to create an immune
response when it is required [30]. However, under cer-
tain circumstances, such as in autoimmune diseases, the
system is able to create a stable oscillatory behaviour
that allows the activation and expansion of self-reacting
Teff cells. Activation of Teff will induce tissue damage,
the counterpart of clinical relapse. In this study we
attempt to explain what conditions are necessary for
triggering the relapsing-remitting autoimmune response
in MS and why in most cases it is not a chronic-pro-
gressive process from the beginning. Given the key role
of relapses in the study and management of MS and
other autoimmune diseases, a broad understanding of
relapsing dynamics is important to promote accurate
diagnosis, patient management and treatment decisions.
Results
Modelling the adaptive immune system reveals the cross-
regulation between Teff-Treg populations a control
mechanism that maintains immune tolerance
We aimed to probe by means of a mathematical model
(see methods and additional files 1, 2 and 3, Figure 2)
whether the relapsing-remitting dynamics in MS can
emerge as a result of the intrinsic control properties of
the immune system that allow it to oscillate (e.g. the
Teff-Treg loop) [30]. We observed two different kinds
of dynamics: healthy regime and autoimmune regime
(Figure 3). Working under a healthy configuration, acti-
vated Teff-Treg populations remain in a dynamic (oscil-
latory) balance without producing immune responses
(Figure 3A), the equivalent of immune homeostasis.
Such activated Teff dynamics does not produce tissue
damage (Figure 3C). However, by decreasing the maxi-
mum activation and proliferation rate of Treg (aR) and
without changing the production or activation rate of
self-reacting resting T-cells, immune homeostasis was
lost and spontaneous immune responses emerged in the
absence of infectious agents, mimicking the relapsing
dynamics of autoimmune diseases (Figure 3B). The pre-
sence of activated Teff cell peaks produces both reversi-
ble and irreversible damage. The sum of both represents
the clinical relapses equivalent to the one observed in
MS patients (Figure 3D). The presence of the Teff-Treg
loop restores the homeostatic levels providing an expla-
nation for why relapses recover and the disease does not
become chronic-progressive.
A significant breakdown of central immune tolerance
might be expected to produce an autoimmune pheno-
type, since the frequency of self-reactive lymphocytes
would be increased, as occurs in the IPEX or APECED
syndromes that are caused by mutations in the Foxp3 or
AIRE genes, respectively [22]. However, performing a
sensitivity analysis by increasing the generation of self-
reactive T cells, we found that if the Teff-Treg loop
parameters are maintained within homeostatic values
(healthy regime), this module can cope with such
increase of self-reacting Teff, even if the amount (per-
turbation intensity) is drastically augmented (data not
shown). Thus, immune tolerance is maintained and the
Figure 2 Model of the adaptive immune system. The model of
the adaptive immune system is comprised of four parts: 1) the
generation of Teff and Treg cells from thymus; 2) T-cell activation by
APCs; 3) the cross-regulation modeled by the Teff-Treg loop; and 4)
T cell activation and memory populations in the tissue. The Teff-
Treg loop is composed of a negative feedback between the two
populations (Teff in red and Treg in blue). The model can be found
in the additional files, and the parameters and initial conditions are
listed in Table 1.
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appearance of autoimmunity is prevented. In order to
observe the induction of autoimmune diseases in this
context, it was necessary to tune down the Teff-Treg
regulatory loop. Therefore our model indicates that
genetic mutations affecting central tolerance are not suf-
ficient to develop autoimmune diseases but require an
impaired Teff-Treg cross-regulation. This is in agree-
ment with the experimental finding that Treg function
is impaired in such hereditary autoimmune diseases
[31]. Finally, we observed in our simulations, using same
parameters but different seeds, that the distribution of
activated Teff cells peaks (relapses) are produced at dif-
ferent intensities and moments, indicating spontaneous
heterogeneity in the temporal distribution of relapses
(Additional File 4, Figure S1). Such differences account
for a different behavior of the reversible and irreversible
damage, indicating clinical heterogeneity.
Decreasing the strength of the Teff-Treg cross-regulation
favours autoimmunity
We explored the autoimmune dynamics in the para-
meter space that controls the Teff-Treg regulatory loop,
repeating the procedure with different input seeds (see
methods) in order to reproduce the stochasticity in the
activation of the immune system by pathogens.
Although other parameters can influence in the
Figure 3 Simulations of the computational model in healthy and autoimmune state. Plots show representative simulations of the antigen-
specific activated-Teff (red) and Treg (blue) population in log scale over 5 years. By changing the parameters of the Teff-Treg loop, we were able
to reproduce two dynamics:A)Healthy state in which the Teff and Treg populations fluctuate at low levels indicating that the system is not
generating an immune response, nor immunopathology;B) Autoimmune dynamics due to a failure in the cross-regulation (Teff-Treg loop),
provoking the expansion and contraction of activated Teff cells. C, D) Simulations of tissue damage: reversible damage (blue), irreversible
damage (red) and total damage (black): C) In healthy configuration the functioning of the immune system (blue line) do not induce significant
tissue damage (black line); D) in autoimmune configuration the peaks of activated Teff induce tissue dysfunction and damage (red line), leading
to the relapsing dynamics (back line).
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outcome dynamic (i.e. h, ke, kr...), it was aR which pro-
vokes the characteristic relapsing-remitting peaks. As we
will see aE turned out to be an important parameter as
well. Because of that we performed a sensitivity analysis
of both parameters running simulations over 1,825 days
(time step of 0.05 days) for each pair of proliferation
rate values in the range of aE = [1:2] and aR = [0.25: 1],
with 0.05 as step value (uniform intervals) (Additional
File 5, Figure S2). Since we are dealing with stochastic
differential equations, 200 different realizations were
performed for each pair of values of the scanned para-
meters. Peaks of activated Teff cells were only observed
when there was a reduction in the strength of the Teff-
Treg regulatory loop, and mainly when the Treg
response was slower (Additional File 5, Figure S2A). We
observed that the simulations only produced high peaks
of Teff activity in a small region of the parameter space.
As expected, the highest peaks of activated Teff cells
were observed when Treg activity and proliferation was
minimal. However, the highest peaks did not always
occur when Teff proliferation rate was at its highest. A
decrease in the Teff proliferation rate for a given seed
does not necessarily imply less severe relapses and, as a
matter of fact, it could produce an increase in relapse
intensity. Such apparently counterintuitive consequences
are due to the strong interaction between the time
dynamics of the system and the time at which the noise
input occurs, as we will see further on. For average
results (Additional File 5, Figure S2B), the population
median tends to grow as the maximum Teff prolifera-
tion rate increases, as well as when the maximum Treg
proliferation rate decreases.
The previous model can be further simplified in order
to keep the dynamically relevant compartments influen-
cing the time behavior. In the reduced model, the T-cell
population system is represented by just two variables,
namely E and R, representing the size of activated T cell
populations and the stochastic effects were eliminated
substituting RE, RR respectively by their expected values
ΛE, ΛR (see eq. 5-6 in methods). In absence of stochastic
events, the system has a stable point (Figure 4). This
point is an attractive point and the system oscillates
with decreasing amplitude until reaching the equilibrium
point (Figure 4B). The value of Teff and Treg cells
reached in the equilibrium depends on the specific
values of every parameter of the model and does not
depend on the initial conditions of the levels of activated
Teff and Treg cells. We observed that when aR
decreases, the equilibrium point moves to higher num-
bers of Teff cells, while Treg cells remain practically the
same point (Figure 4A). Moreover as aR decreases the
shape of the spirals gets longer along the Y axis, corre-
sponding to Teff cells, and becomes radically narrower
in the X axis, which corresponds to Treg cells (Figure
4B). The sensitivity analysis of the system showed that
the shape of the spirals do not significantly change
when the maximum Teff proliferation rate aE changes,
although the value of the equilibrium point increases in
the Treg axis. If we carry the system to extreme values,
aR > 1, this latter dynamic might represent a hypersen-
sitive Treg response, which could be beneficial to pre-
vent autoimmunity, although perhaps at the cost of not
being able to control infections or even, inducing immu-
nodeficiency. This mechanism could speed up the Treg
response, allowing a pathogen to establish a chronic
infection. As an example, it has been proposed that
many pathogens responsible for persistent chronic infec-
tions highjack immunological regulatory mechanisms
[32]. In summary, our analysis suggests that the Teff-
Figure 4 State-space analysis of the Teff-Treg loop. The state-
space analysis was done with the simplified T-cell population model
(eq. 2). The X axis represents the activated Treg population and the
Y axis activated Teff cells. A)By plotting both populations with
different levels of aR the equilibrium point moves to higher
numbers of Teff cells, remaining practically the number of Treg cells
in the same point.B)State-space plot corresponding to the two
extreme values for aR: 0.21 and 2.0, showing an abrupt change in
the dynamics.
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Treg regulatory loop is critical for the outcome of the
system (tolerance, response to infections, autoimmunity
and immunodeficiency).
Predicting relapses in MS
In order to evaluate and validate our model, we com-
pared computational simulations of the reversible
damage (which are highly correlated to the T cell infil-
tration in the CNS) with the contrast enhancing lesion
(CEL) time series from 9 patients with MS. The model
was able to partially forecast the CEL time series
(Figure 5A), with correlation distributions centered on
coefficient values of 0.55 and in some cases up to 0.75
(Figure 5B). These results indicate that Teff-Treg cross-
regulation is a key element in governing the oscillatory
behavior of the immune system and drive the presence
of relapses in MS, but at the same time indicate a signif-
icant component of stochasticity in the generation of
clinical relapses, limiting our predictive ability.
Dynamics of the Teff-Treg regulatory loop after
perturbation: Implications for immunotherapy
The effects of Treg and Teff perturbations on the sys-
tem were studied in order to gain insight into the
dynamics of the immune system, mainly on the effect of
noise, as well as to predict the effect of immunothera-
pies targeting either effector or regulatory T cell popula-
tions. By analyzing the E-R state-space before and after
the perturbation, we identified the different outcomes in
the system. In the absence of perturbations, the trajec-
tory of the state-space of both populations is a spiral
that moves clockwise until reaching the equilibrium
point, and the change of the initial conditions produces
a new trajectory that also moved clockwise towards the
same equilibrium point (see Figure 6: only a portion of
the trajectory is shown for clarity). The effect of intro-
ducing an impulse of either naïve Teff or Treg cells pro-
duced a jump to another trajectory. This is equivalent to
restarting the model under different initial conditions,
the equilibrium point remaining the same.
From the therapeutic point of view, modulating the
levels of Teff and Treg populations as possible immu-
notherapies has several implications that a priori cannot
be intuitive. The time at which the therapy is introduced
may be important, since depending on this factor the
effect can be beneficial or deleterious (Additional File 6,
Figure S3). Thus, if a therapy increasing the levels or
activity of Treg is administered when the dynamic of
the effector population is decreasing, the effect of the
Treg immunotherapy would be deleterious. In the same
way, although an immunotherapy with Teff cells would
be deleterious for autoimmunity, depending on the dose
timing could be protective. If a dose with Teff cells is
administered when the dynamic of the regulatory popu-
lation is decreasing, the effect of the Teff immunother-
apy would be beneficial although it can seem
paradoxical. This prediction can explain why targeting
IL-17A, an interleukin with pro-inflammatory functions,
might not have beneficial effects if they are administered
at the wrong time or dosage [33].
For example, for modeling cell therapy with Treg cells,
we compared the sensitivity to a Treg perturbation under
health (aR = 1) and autoimmunity (aR = 0.25) using the
same conditions by analyzing the changes in the trajectory
of the phase-space between Teff and Treg cell populations
after Treg perturbation and the effect in the dynamics of
reversible an irreversible damage (Figure 6). Under healthy
configurations and after the perturbation (Treg therapy),
Figure 5 Prediction of relapses for clinical datasets A)
Simulations of CEL time series: simulations of the reversible damage
in months (in blue) from the computational model reproduce the
dynamics of CEL dataset from patients with MS (in red); B) Pearson’s
correlation coefficients between CEL series and reversible damage.
Each correlation distribution was obtained by comparing 2,000
simulated series and each patient series.
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the system jumps to a new trajectory (Figure 6A) where
the new maximum value reached by activated Teff is
higher than in the initial trajectory. However, in the auto-
immune condition and after the Treg impulse, the system
also jumps to a new more distant trajectory (Figure 6C).
The model was more sensitive in this autoimmune regime
and while the maximum value of activated Teff cells was
less than 104 cells in the healthy regime, it reached more
than 109 activated Teff cells in the autoimmune regime. In
consequence, the damage both reversible and irreversible
produced is very noticeable during an autoimmune regime
(Figure 6D) while it remains insignificant during a healthy
regime (Figure 6B).
Discussion
The study of the relapsing-remitting dynamics of MS
and other autoimmune diseases can have practical bene-
fits for patient management. The unpredictability of
relapses in MS is one of the most disturbing aspects of
the diseases reported by patients. Given the key role of
relapses in the management of the disease, a broad
understanding of relapsing dynamics is important to
Figure 6 Modeling Treg cell therapy. A)Healthy configurations: while the system is moving clockwise on a spiral trajectory that moves towards
the equilibrium point, the model was perturbed with an impulse of Treg cells (only a portion of the trajectory is shown for clarity). The
perturbation was introduced near to the maximum possible value of activated Treg. After the impulse, the system jumps to a more distant spiral,
where the new maximum value reached by the activated Teff is greater than that on the initial trajectory. B)In the healthy configuration
reversible and irreversible damage result almost imperceptible. C) Autoimmune configuration: while the Teff-Treg loop is driving an autoimmune
regime, the model was perturbed with the same impulse as above. The effect of the perturbation was qualitative similar to that in the healthy
regime, but not quantitatively, showing the hypersensitivity of this kind of regime in the model. D)Both reversible and irreversible damage
resulted evident when the system was working under autoimmune conditions.
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perform an accurate prognosis, improving patient’s
management and therapeutic decisions. In order to gain
insights in the mechanistic basis of this relapsing
dynamics we developed a mathematical model of the
adaptive immune system. We aimed to assess the
hypothesis that the characteristic relapsing-remitting
dynamics of autoimmune disease emerges as a result of
the intrinsic control properties of the immune system.
Based on our simulations, we found that immune toler-
ance, defined in our model as the capacity to cope the
activation of effectors T cells, is an emergent property
of the Teff-Treg cross-regulation. This indicates that the
Teff-Treg loop is a powerful control module that regu-
lates the adaptive immune system when activated by
stochastic environmental factors. A pathological
dynamic regime of the Teff-Treg loop created a pulsing
dynamics in which the expansion of the Teff population
transiently escapes the control of Treg population, creat-
ing the relapses typical of autoimmune diseases such as
MS. In our model, relapses mainly arise upon the failure
in the Treg response and were mainly driven by sto-
chastic process that might correspond either to thymic
production of new self-reacting T cells or from random
sporadic infections. Interestingly, the frequency of such
stochastic events where not the main factor producing
relapses, but the severity in the dysfunction of the Teff-
Treg cross-regulation was the main responsible of
relapse frequency and severity. This finding can explain
why the relapse activity in patients with MS is quite
stable during the relapsing-remitting phase, because it
would mainly depend on the dysfunction of the immune
system, but make relapses very difficult to predict.
Our model shows that the pathologic dynamic regime
in autoimmune conditions become stationary and makes
the autoimmune process chronic but relapsing instead of
progressive. In this scenario, autoimmunity can be con-
sidered as a dynamic disease [34,35], in which the patho-
logical state arises through the emergence of stationary
stochastic dynamics in the immune system that over-
comes immune homeostasis. Although our study was
mainly inspired in the dynamics of MS, we believe it can
provide insights about the dynamic of other autoimmune
diseases, since many of them also have relapses (e.g.
Lupus or Rheumatoid Arthritis) but also chronic, non-
relapsing autoimmune diseases such as type 1 diabetes
might also display relapsing inflammatory bursts [36].
Thus, our study supports the view of autoimmune dis-
eases as complex disease produced not by a single mole-
cular or cellular event or governed by environmental
challenges, but rather by the combination of many factors
that deregulate the control mechanisms in the immune
system [37].
Our study highlights the critical role of the cross-regu-
lation of T cell populations in peripheral tolerance and
in the generation of autoimmune diseases. Although
both the loss of the central tolerance and the impair-
ment of the Teff-Treg loop can contribute to the gen-
eration of autoimmunity, our model suggests that the
breakdown of cross-regulation and not central tolerance
leads to this kind of relapsing autoimmune dynamics.
This result is in agreement with the fact that the major-
ity of autoimmune diseases are sporadic and not related
with mutations in genes controlling central tolerance,
such as in the IPEX or APECED syndromes [22], and
that impairment of Teff-Treg population is also required
even in monogenic autoimmune diseases [32]. Another
conclusion from our study is that the autoimmune dis-
eases can result from the weakening of the peripheral
tolerance, particularly the control exerted by Treg over
effector/auto-reactive T cells. There is already experi-
mental evidence supporting a role of such control loop
on the prevention of some autoimmune disease. Particu-
larly there is evidence of several genetics defects weak-
ening this loop that are clearly associated with
autoimmunity [22] as well as previous mathematical
models supporting this idea [38]. Our results show that
defects on central tolerance (particularly those increas-
ing the frequency of generation of auto-reactive T cells)
might not be sufficient to induce autoimmunity. There
is already experimental evidence proving this fact in ani-
mal models. Particularly, transgenic mouse model have
shown that a thymus generating more than 90% of its
total output of a single anti-MBP auto-reactive T cell
clones without causing autoimmunity, because of the
peripheral control exerted by the remaining 10% of the
T cell repertoire that happens to contain Treg [39].
Previous models of cross-regulation between effector
and regulatory cells have shown bi-stable regimes
[29,40]. In one of the stable points, corresponding to the
healthy states, the Treg population controls the effector
population, while in the second stable point, interpreted
as the autoimmune state, effector cells outcompete or
predominate over regulatory cells. These models provide
an explanation for the etiology and natural history of
chronic-progressive autoimmune diseases such as type I
Diabetes or the progressive subtypes (non-relapsing) of
Lupus or MS, as the result of a switch to the pathology
stable attractor. However, relapsing-remitting dynamics
of autoimmune diseases such as those found typically in
MS, Rheumatoid Arthritis or Lupus still lack of a theo-
retical framework. The major contribution of the model
introduced in this paper is a dynamical explanation for
such relapsing-remitting dynamics. Even though the
cross-regulation makes that both populations always
stay within the basin of attraction of a unique steady
stable point, there are configurations whose trajectories
produce temporal relapses in presence of environmental
stochastic events. One basic assumption of our model is
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that the oscillatory dynamics of the immune systems
will depend the prey-predator model with stochasticity
[41]. However, in our model the stochastic environmen-
tal factors were modeled as a train of impulses influen-
cing the Teff growth (prey) rate and the Treg death rate
(predator). For this reason, our model differs from pre-
vious predator-prey models because the stochasticity
component come from introducing either Teff or Treg
randomly using a train of impulses, independently of the
T cell population density used in other models [41].
Our results also show that the onset of the relapse is
triggered by stochastic events such as the random thy-
mic generation of auto-reactive Teff or Treg cells or
sporadic common infections that activate the immune
system. However, the duration of each relapse and the
overall relapsing frequency are under the control of the
dynamics of Teff-Treg loop. This result might help to
explain why previous attempts to identify external fac-
tors triggering relapses failed to provide clear explana-
tions [2,11]. Moreover, predicting the appearance of
new relapses will be difficult, not only because we
would lack sufficient knowledge about the dynamics of
the immune system in a given individual at a given
time, but also due to the influence of the stochastic
events.
In our study we model the reversible tissue damage in
order to provide a comprehensible link to the active
lesions in CNS observed in patients with MS. Therefore,
we compared long-term simulations of reversible tissue
damage with the CEL dataset from patients with MS.
The simulations obtained closely reproduced the oscilla-
tory behavior of the CEL dataset, obtaining moderate to
high correlations and reproduced the two-phase beha-
vior (the relapsing-remitting dynamics). In this way, this
model explains dynamics of autoimmunity with a basic
cyclic nature. This is important, since several human
autoimmune diseases are documented to have a cyclic
behavior, although this is not the only class of dynamics
observed for autoimmunity (e.g. type 1 diabetes). More-
over, mathematical models of T cell vaccination have
explored the dynamics of the immune system after gen-
erating anti-idiotipic Treg for switching-off the autoim-
mune response, explaining the cyclic dynamics of
autoimmune disease [42,43]. However, the limited pre-
dictive ability suggest that either other biological factors
not include in the model or, more probably, the stochas-
ticity of T-cell activation due to random infections
might account for a significant proportion of the tem-
poral distribution of relapses. Also, although our model
is able to reproduce the relapsing dynamics of MS,
other models considering other factors might also be
able to provide similar explanations.
From the therapeutic point of view, our results may
have several implications. First, our analysis indicates
that autoimmunity is a dynamic phenomenon. Thus,
perturbing the Teff and Treg populations might produce
different outcomes depending on the control parameters
of the immune system in a given patient and the timing
of the intervention, but without modifying the underly-
ing dynamics. Accordingly, therapeutic approaches to
treat autoimmune diseases that involve either decreasing
Teff populations (e.g. through chemotherapy, anti-CD52
or anti-CD20 mAb therapy) or increasing Treg popula-
tions (e.g. Treg cell therapy) will not cure the disease,
since they are aimed to keep the values of both popula-
tions in the range observed in healthy state but without
restoring the control of the immune system to that of
the healthy state. From a systems biology perspective,
therapeutic interventions should be designed to restore
the dynamics of the system to the healthy state or at
least to a less deleterious dynamic [44,45]. In order to
efficiently modulate the dynamics of the immune system
it is necessary to know in which region of parameter
space the immune system of a given patient is acting at
any time, as well as to identify which control mechan-
ism can be targeted [44,46]. As we found in the pertur-
bation analysis, considering the outcome of increasing
the Treg population or decreasing the Teff population
to treat autoimmune diseases, intervening at different
times and with different perturbations, might be benefi-
cial. The timing and dose will be specific for a given
patient or subgroup of patients, implying the need for
personalized medicine. Nevertheless, it will be necessary
to translate the critical parameters to specific molecular
and cellular markers of the immune system in order to
be able to apply it to human immunotherapy [44,45].
Our study has several limitations. As commented
before, despite the emerging importance of Treg in the
immune system, fundamental parameters of the biology
and homeostasis of these cells, such as their lifespan,
turnover, and recirculation properties remain unknown.
Also, while we analyze the cross-regulation of Teff and
Treg populations from a systemic point of view, many
other aspects of the immune response that may also be
important, were not contemplated, such as the innate
immune systems activity, regulation of the effector
response in the tissue, the role of the T-cell immune
repertoire or the control of the immune response on T-
cell activation [37,47]. However even with this simplified
model of the immune system, we were able to show
that autoimmune diseases can arise as a dynamic phe-
nomenon and we could identify the critical contribution
of the Teff-Treg loop in the control of the immune
response, providing a theoretical framework for the
understanding of the relapsing dynamics in autoimmu-
nity. Also, the induction of an autoimmune response in
our model requires some minimal changes in the para-
meter values. This may represent the accumulation of
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the genetic background (e.g. HLA class II susceptibility
alleles (DRB1*1501), IL2R or IL7R for MS) [48], in con-
junction with the shaping of the immune repertoire dur-
ing ontogeny and the presence of stochastic infectious
challenges for generating individuals susceptible to
develop autoimmune diseases.
Conclusions
The relapsing dynamic in MS may derive from the
emergent properties of the immune system running in a
pathological state, a fact that has implications for pre-
dicting disease course and developing new therapies for
MS. This pathological state might be produced by the
combination of many factors that deregulate the control
mechanisms in the immune system (instead of by a sin-
gle molecular or cellular event). Due to the fact that the
results of this study are qualitative rather than quantita-
tive, the conclusions must be considered as highly plau-
sible conjectures, which have to be experimentally
tested.
Methods
Subjects
Data for this study were previously generated at the
NINDS-NIH [49]. Patients whose data are presented
were enrolled in a NIH/NINDS/IRB approved protocol.
Each subject has signed an informed consent prior to
participate to the study. We studied 9 patients with
RRMS, free of immunomodulatory treatment, who
underwent monthly MRI with gadolinium for 48
months. We recorded the number of CELs for each
consecutive month on the MRI, the Expanded Disability
Status Scale (EDSS) for measuring clinical disability and
the presence of clinical relapses (see additional files).
Patients were recruited after obtaining wrote informed
consent. The study was approved by the IRB at NIH.
Mathematical modeling
The model was simulated in the VENSIM (Ventana Sys-
tems, Inc., MA, US) and MATLAB (The Mathworks,
MA, US) computing environments. The initial values,
parameters and their references are shown in Table 1.
Despite the emerging importance of Teff and Treg in
the immune system, fundamental parameters of the
biology and homeostasis of these cells, such as their life-
span, turnover, and recirculation properties remain
unknown. The parameters were estimated using good-
ness of fit plots.
The T-cell population dynamic
The model is a simplification of the adaptive immune
system focusing on the activation of T lymphocytes, in
their proliferation and subsequent migration to tissues
where they exert their effects. The T-cell population
variables represent pool of antigen-specific T cells
participating in a given immune response and not the
overall T cell repertoire. The conceptual core used to
develop this model (Figure 2) basically has three parts:
Teff-Treg regulatory loop, the stochastic processes and
the tissue damage production.
dEr
dt
= IE − Erδ − Erβ + Eη (1)
dRr
dt
= IR − Rrδ − Rrβ + Rη (2)
dE
dt
= Erδ − Eη + EαEkR
h
kR
h + Rh
− EγER
h
kR
h + Rh
(3)
dR
dt
= Rrδ − Rη + RαRE
h
kE
h + Eh
− RγE (4)
where Er, Rr, E, R represent the size of the resting
Teff, resting Treg, active Teff, active Treg cell popula-
tion respectively. Several parameters are assumed to be
identical for both Teff and Treg types: h is the rate at
which the cells return to the resting state; δ is the cell
activation rate; b is the rate at which the resting cells
become anergic or die. Other parameters were assumed
Table 1 Parameters of the model
Intial Conditions Symbol Values
Resting Teff cell population size Er En0 = 0 cells
Resting Treg cell population size Rr Rn0 = 0 cells
Activated Teff cell population size E Ea0 = 1000
cells
Activated Treg cell population size R Ra0 = 200
cells
Reversible Damage l l0 = 0
Irreversible Damage L L0 = 0
Parameter description Symbol Values
Antigen Presentation δ 1 day-1 (35)
Anergy b 0.01 day-1
Memory h 0.01 day-1
Maximum Teff proliferation rate aE [1:2] day-1 (36)
Maximum Treg proliferation and activation
rate
aR [0.25:2] day-1
Teff death, anergy and migration Rate gE 0.2 day-1 (37)
Treg death, anergy and migration Rate gR 0.2 day-1
Teff cell population sizes leading to half
maximal effect counterpart
Ke 1000 cells
Treg cell population sizes leading to half
maximal effect
Kr 200 cells
Hill coefficient h 5
Reversible damage rate d1 1 day
-1
Irreversible damage rate d2 0.02 day
-1
Threshold a 22800 cells
Recovery r 0.1 day-1
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to be cell type specific: IE, IR are the stochastic inputs of
Teff and Treg cells respectively; aE, aR are maximal pro-
liferation rates; gE, gR the clearance rates. The cross-reg-
ulatory interactions between the Teff and Treg
populations are modeled as Hill functions, where kE, kR
are respectively the Teff and Treg population densities/
sizes leading to half maximal effect on their counterpart.
Finally, h is the Hill coefficient, which controls the
response sensitivity. Table 1 contains the list of para-
meters and values of the model.
In order to solve the model analytically, the T-cell
population system was reduced to the two variables E
and R representing the size of activated T cell popula-
tions. To eliminate the stochastic effects, the terms
representing the influx from resting cell populations
were set to constant substituting RE, RR respectively by
their expected values ΛE, ΛR respectively.
dE
dt
= Eδ − Eη + EαEkR
h
kR
h + Rh
− EγER
h
kR
h + Rh
(5)
dR
dt
= Rδ − Rη + RαRE
h
kE
h + Eh
− RγE (6)
Tissue damage
We coupled to the T-cell population model (eqs. 1-4,
Figure 3A) with two additional equations that represent
the damage caused by activated Teff cells on the target
tissue. With such equations we aim to provide a com-
prehensible link between autoimmune activity and clini-
cal relapses in patients with MS:
dl
dt
= d1E′ − lr − d2l (7)
dL
dt
= d2l (8)
where l, L are reversible and irreversible damage
respectively; d1, d2 are the rate constants at which the
damage is produced and recovered respectively; and E’
= (E/a)2 is the second order effect of Teff cells on
damage. l and L are output variables that are affected
by, but have no feedback on the T cell population
dynamics.
Theory
The model was designed according to certain assump-
tions. Such assumptions qualitatively describe relation-
ships that have been experimentally observed.
The Teff-Treg regulatory loop
Teff-Treg regulatory loop was modelled as a negative
feedback loop between two competing populations,
activated Teff and activated Treg cells. This negative
feedback is the consequence of a negative influence of
Treg over Teff, and a positive influence of Teff over
Treg [14-18]. It is essentially a prey-predator system,
where Teff cells act as prey and Treg cells as predators.
Treg inhibition of Teff in the model accounts for dif-
ferent known mechanisms: suppression by competition
for growth of survival factors as IL-2 [16,18], cell-to-cell
contact inhibition [16], secretion of immunosuppressive
cytokines and the induction of apoptosis both in vitro
and in vivo [50]. In this model, the Treg population has
a negative effect on Teff proliferation. There is an inhi-
bition of Teff proliferation due to the presence of acti-
vated Treg cells. On the other hand, the regulatory
population exerts a positive effect on Teff migration,
anergy and death (gE). That is, the presence of Treg
cells triggers specific mechanisms which produces an
increase of the apoptosis and anergic rate of activated
Teff population, like its migration to the tissue [28,51].
This flow of Teff (gE) controls the permanence expec-
tancy of Teff in the activated proliferative state. Since
this expectancy of the Teff population depends on the
Treg density at each moment; it increases to 5 days in
the absence of activated Treg cells. This maximum
expectancy (5 days) was estimated based on the knowl-
edge that the activated-T cells migrate to the target tis-
sue 5-7 days after activation [51]. The estimated value
for the permanence expectancy of the activated-Treg
cells in the draining lymph node (gR) is independent of
the Teff population in our model and keeps constant at
5 days. In summary, the negative influence of Treg on
activated-Teff cells resides in the inhibitory signals pro-
duced by activated-Treg cells, which impair their prolif-
eration [17,52] and promote both apoptosis [50] and
migration to the tissue [28].
There is experimental evidence of the existence of a
positive effect of Teff cells over Treg population: Treg
cells proliferate in response to immunization in vivo
[28,40,53], and in vitro when stimulated with a TCR
trigger together with Teff cells (28). This contrast with
the previous notion than Treg were anergic, but the lack
of proliferation of Treg in early experiments were due to
the in vitro conditions and the new in vivo data demon-
strate they can expand after immune system activation
[54]. They proliferate and accumulate locally in response
to transgenically expressed tissue antigen whereas their
CD25- cell counterparts are depleted at such sites [54].
These observations support a model in which Treg
population dynamics are shaped by the local environ-
ment. Therefore, there is a positive influence of Teff
cells over Treg population: Activated Teff cells produce
signals that evoke the expansion of activated Treg cells
and that enhance their suppressive function in vitro and
in vivo [29]. The positive influence was also assumed to
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operate according to a Hill function which links the
activation of Teff cells with the expansion and regula-
tory activity of Treg cells [29]. Thus the suppressor
activity of Treg become stronger in the presence of
increasing levels of Teff cells, mimicking molecular
mechanisms such as conversion of Teff to the Tr1 phe-
notype after stimulation [24,52], or the influence of IL-2
[40,55,56].
T-cell activation
Resting auto-reactive Treg and Teff cells are unable to
participate in an immune response until they become
activated by antigen on APCs, including self-antigens
[39], through molecular mimicry between self-antigens
and other antigens, or other proposed mechanisms [47].
Since we aim to study the regulation between activated
T populations, T-cell activation by APC was modelled
as a deterministic process for simplicity: every resting T
cell which is produced by the thymus will become acti-
vated after 24 hours, since T-cell activation by APC
extends from 16 to 28 hours [57]. Once cells are acti-
vated, the cross-regulation between activated Teff and
Treg cells defining the Teff-Treg loop modulates the
outcome of the immune response.
Stochastic process
Stochastic fluctuations in biological systems are ubiqui-
tous and may drastically modify the deterministic pre-
dictions [41,58,59]. Gaussian white noise variations are
usually added to the predator death rate and prey birth
rate to model the continuous environmental fluctuations
[60]. However, to gain more realistic and general under-
standing of the effect of environmental fluctuations
leading to extinction of the species, it is highly desirable
to adopt so-called stochastic pulse trains rather than
Gaussian white noise as the description of fluctuations
[41]. The thymic production of new resting T cells is
essentially a stochastic process with a series of discrete
events as cells with a relevant specificity happen to be
produced by V(D)J recombination and exported after
maturation. In this way we modelled the influx of rest-
ing cells as spike trains instead of Gaussian noise. In
this case it is desirable to take into account discrete and
drastic actions for modelling the appearance of new
resting/naïve T cells, which are going to be activated.
We did not use a Gaussian white noise since it always
assumes the presence of continuous perturbations, while
in real systems there are some unavoidable sparse, yet
drastic, impulses that may qualitatively change the sys-
tem behaviour and even completely invalidate the
deterministic predictions. As a consequence, the sto-
chastic perturbations are intrinsically non-Gaussian
and a discrete fluctuation model was preferred. In the
present model, the escape of self-reactive naïve T-cells
from deletion in the thymus and self-reactive resting
T-cells which are capable to be activated under specific
environmental triggers, such as infections, were mod-
elled using a stochastic function by uniformly distribu-
ted production of resting Teff and Treg cells over
time. The Teff and Treg perturbations represent trains
of 100 randomly distributed impulses per year. This
modelling reflected the fact that the generation of a
given self-reacting T-cell is a random event and that
consecutive events are not related to one another [61].
Changing the seed of the random number generator
corresponds to the generation of T-cells at different
times along the course of the simulation, but maintain-
ing the same frequency and distribution of cell produc-
tion. Due to these random perturbations, the model
becomes a system of stochastic differential equations
where the Teff-Treg loop is fed with a small noise
input of new resting T cells.
Simulations
Simulations are initiated with 0 resting Teff and Treg
cells, and 1,000 and 200 activated Teff and Treg cells
respectively. Reversible and irreversible damage levels
are initiated with 0. We performed a sensitivity analysis
of wide range of values the different proliferation rates
(aE) and (aR). The time span of each simulation was
1,825 days (5 years). This period was chosen because
clinical relapses in autoimmune diseases such as MS
range from months to years and the simulations were
intended to represent this process. Depending on the
values of aE and aR, the evolution of activated-Teff cells
may differ. Simulations of the healthy regime (tolerance,
immune homeostasis) were carried out using aE = 2
and aR = 1. For the autoimmune regime we used the aR
= 0.25 parameter, which reflected a weak response of
the Treg population in autoimmune diseases. The
amplitude of Teff cell burst was similar to experimental
data [28].
Sensitivity analysis
Sensitivity analysis of the T-cell population model was
performed by running simulations over 1,825 days for
each pair of proliferation rate values in the range of aE
= [1:2] and aR = [0.25: 1], with a time resolution of 0.05
days (the parameter values were tested in increments of
0.05). The maximum value reached by the activated-Te
cells was retained from each simulation. Since we are
dealing with stochastic differential equations and we are
interested in extracting the global behavior of our sys-
tem, the procedure was repeated for a large number of
seeds (200 different realizations of the noise for each
pair of values of the scanned parameters). We checked
that 200 simulations per each pair of proliferation rates
were enough to reach reasonably convergent results (the
convergence for the frequency is much faster than the
convergence for the intensity of the relapses). We
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empirically calculated the convergence when the differ-
ence between the maximum and minimum value of the
signal is less than 10-5.
Correlation analysis between simulations and clinical time
series
In an attempt to compare the clinical data from MRI
(CEL series) and the simulated series of the reversible
tissue damage, we made two simple processing steps.
First, in order to have the same temporal resolution in
both series (real and simulated data), the simulated ser-
ies were discretized by taking only one point per month.
Second, because the experimental and theoretical obser-
vables are not directly comparable, we calculated the
increment or decrement of the variable in both time ser-
ies types at each time t. This was done by subtracting
the value at t-1 from the value at t for the whole series.
Hence, new processed series have a value of zero when
the disease neither deteriorates nor improves. Positive
values represent the disease exacerbation and negative
values a decrease in the disease activity. For clarifying,
we denominated the processed series from real data
(CEL time series) and from the simulations as “disease
evolution” and “in-silico evolution” respectively. We cal-
culated the “disease evolution” for the nine patients with
MS whom underwent monthly MRI for 48 months. The
“in-silico evolution” was also calculated for 2000 simula-
tions under autoimmune configuration (aR = 0.25) with
a time window of 120 months. That is, the “in-silico
evolution series” are longer than the 9 “disease evolution
series”. The best Pearson’s correlation coefficient when
sliding each “disease evolution series” (48 points) along
the “in-silico evolution series” (120 points) was obtained
and plotted in a histogram (Figure 5).
Additional material
Additional file 1: Model equations for Vensim software as text. It
contains all the equations, auxiliary variable definitions and parameter
values of the model (doc file).
Additional file 2: The model in Vensim software code. It contains the
model. It’s ready to run using the Vensim software (mdl file). Vensim can
be downloaded from http://www.vensim.com/
Additional file 3: Dataset CEL from patients with MS Data from 9
patients with RRMS who underwent monthly MRI with gadolinium
for 48 months. It showed the number of CELs for each consecutive
month on the MRI, the Expanded Disability Status Scale (EDSS) for
measuring clinical disability and the presence of clinical relapses (excel
file).
Additional file 4: Figure S1. Clinical heterogeneity: Influence of
timing on the generation of self-reacting T-cells in the dynamics of
the immune system. Four simulations (over 5 years) of the same model
(same parameters and initial conditions) are presented for four different
seeds generating the naïve Teff and Treg populations. We used a
parameter configuration that allows the generation of autoimmune
dynamics (aR = 0.25). Left: Dynamics of activated Teff cells. Right:
Evolution along time of the reversible, irreversible and total damage.
Additional file 5: Figure S2. Sensitivity analysis of the model A. At
individual level: The figure shows the sensitivity analysis when changing
the Teff and Treg proliferation rates for four different seeds. The X axis
corresponds to the maximum Treg proliferation rate, aR, and the Y axis
to the maximum Teff proliferation rate aE. The Z axis shows the average
relapse intensity reached by activated-Teff cells during a 5 year
simulation (Z axis). Each blanket corresponds to a different seed. B. At
global level: We realize 200 different simulations per each pair of
proliferation rates; Average of 200 different “A” blankets.
Additional file 6: Figure S3. The effect of perturbing the Te-Treg loop
with a pulse of Treg and Te cells. The system, under autoimmune
configuration, was perturbed at different times (sectors) with different
intensity pulses of Treg/Te cells and the graphs display the phase space
of the Te-Tr loop. The number of activated-Treg cells is plotted on the X
axis and the number of the activated-Te cells on the Y axis. Both
populations move clockwise along a spiral path to the equilibrium point
in the absence of perturbations. Because the Te and Treg populations
fluctuate under a negative feedback control, there are four feasible
dynamic states. Sector I: both activated Te and Treg populations are
growing. Sector II: the activated-Treg population is growing and the
activated-Te population is diminishing. Sector III: the activated-Treg
population is diminishing and activated-Te population is growing. Sector
IV: the activated-Te population is growing and activated-Tr population is
diminishing. The trajectory before the perturbation is depicted in black
and after in red. Treg impulses: A. A small Treg perturbation in sector I
leads to a jump to a closer trajectory. B. A large Treg perturbation in
sector I leads to a jump to a more distant trajectory. C. a small Treg
perturbation in sector IV leads to a jump to a closer trajectory. D. a large
Treg perturbation in sector IV leads to a jump to a more distant
trajectory. Any other perturbation in sector II and III, irrespective of its
intensity, will move the system to another more distant trajectory (data
not shown). Te impulses: E. A small Te perturbation in sector IV leads to
a jump to a closer trajectory. F. a large Te perturbation in sector IV leads
to a jump to a more distant trajectory. G. A small Te perturbation in
sector III leads to a jump to a closer trajectory. H. A large Te perturbation
in sector III leads to a jump to a more distant trajectory. Any other
perturbation in sector I and II will move the system to a more distant
trajectory, irrespective of its intensity (data not shown).
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